Overcoming Candida biofilm resistance: targeting persister cells with probiotic-derived metabolites

TL;DR

This paper explores using probiotic metabolites to target persister cells in Candida biofilms, offering a potential new treatment for drug-resistant fungal infections.

Contribution

The paper introduces the novel use of probiotic-derived metabolites as a potential adjunct therapy to overcome Candida biofilm resistance.

Findings

Probiotic-derived metabolites show potential in inhibiting biofilm behavior and survival.

Persister cells in biofilms are a key target for new treatment strategies.

Adjunct therapies using metabolites could enhance existing antifungal treatments.

Abstract

Candida biofilms pose a significant complication in clinical settings due to antifungal drug tolerance and the presence of persister cells. Biofilm-mediated resistance is influenced by several associated factors, including the high density and extracellular matrix characteristics of the biofilm, metabolic downregulation, efflux pump activity, and stress-response signaling pathways, which ultimately diminish drug permeability and effectiveness. Within biofilms, persister cells form a small subpopulation of cells with unique phenotypic traits that enable them to survive lethal antifungal exposure and promote the recurrence of infection. Failure of antifungal treatments in eliminating biofilm and their resilient communities suggests a need for new, adjunct treatment options Recent findings have highlighted the therapeutic potential of probiotic-derived metabolites for inhibiting certain aspects of biofilm behavior and survival. These postbiotic compounds could offer a multi-faceted, low-toxicity treatment approach that may be used as an adjunct with existing antifungal therapies. Future investigations incorporating mechanistic studies, biofilm models, and drug product development for metabolite formulations could lead to a new treatment strategy for persistent Candida infections.

Figures